| 黄建华,廖舆珍.艾普拉唑联合消化内镜治疗消化性溃疡出血疗效分析[J].中国烧伤创疡杂志,2025,(4):324~328. |
| DOI： |
| 中文关键词: 消化内镜 艾普拉唑 消化性溃疡 出血 胃酸 氧化应激 |
| 英文关键词:Digestive endoscopy Ilaprazole Peptic ulcer Bleeding Gastric acid Oxidative stress |
| 基金项目: |
|
| 摘要点击次数: 15 |
| 全文下载次数: 34 |
| 中文摘要: |
| 【摘要】 目的 分析消化性溃疡出血患者应用艾普拉唑联合消化内镜治疗的效果。 方法 选取 2022 年 2 月 至 2024 年 2 月清流县总医院收治的 184 例消化性溃疡出血患者作为研究对象, 按照随机数表法将其分为研究组 (92 例) 与对照组 (92 例), 研究组患者采用艾普拉唑联合消化内镜治疗, 对照组患者采用泮托拉唑联合消化内镜治疗, 对比两组止血效果、胃肠激素水平、生长因子水平、氧化应激指标水平、临床疗效以及不良反应发生情况。 结果 干预 24、72 h 时, 研究组患者止血例数明显多于对照组 (χ 2 = 4.935、4.948, P = 0.026、0.026); 止血后 30 d 内, 研究组患者再出血例数与对照组无明显差异 (χ 2 = 2.091, P = 0.148); 治疗7、14 d后, 研究组患者胃蛋白酶原Ⅰ (PGⅠ)、胃泌素-17 (G-17) 以及脂质过氧化物 (LPO)、丙二醛 (MDA) 水平均低于对照组 (PGⅠ: t = 3.919、3.699, P 均< 0.001; G-17: t = 3.672、4.585, P 均< 0.001; LPO: t = 7.088、6.421, P 均< 0.001; MDA: t = 4.745、5.394, P 均 < 0.001), 而碱性成纤维细胞生长因子 ( bFGF)、血管内皮生长因子 (VEGF) 以及一氧化氮 (NO)、超氧化物歧化酶 ( SOD) 水平均高于对照组 ( bFGF: t = 4.026、4.791, P 均< 0.001; VEGF: t = 4.215、4.661, P 均<0.001; NO: t = 6.901、9.276, P 均<0.001; SOD: t = 3.732、3.386, P< 0.001、P= 0.001); 治疗结束后, 研究组患者临床疗效明显优于对照组 (Z= -2.619, P= 0.009); 治疗期间, 研究组患者不良反应发生率与对照组无明显差异 (χ 2 = 0.898, P= 0.343)。 结论 艾普拉唑联合消化内镜治疗消化性溃疡出血, 可明显加快止血速度, 且能够有效降低胃酸分泌水平及氧化应激损伤程度、提高生长因子水平, 进而促进溃疡的愈合, 疗效显著。 |
| 英文摘要: |
| 【Abstract】 Objective To analyze the clinical efficacy of ilaprazole combined with digestive endoscopy in the treatment of peptic ulcer bleeding. Methods 184 patients with peptic ulcer bleeding admitted to Qingliu General Hospital from February 2022 to February 2024 were enrolled as research subjects, and divided, using the random number table, into the study group (n = 92) and the control group (n = 92). Patients in the study group were treated with ilaprazole combined with digestive endoscopy, while patients in the control group were treated with pantoprazole combined with digestive endoscopy.The hemostatic effect, levels of gastrointestinal hormone and growth factor, oxidative stress indexes, clinical efficacy, and the occurrence of adverse reactions were compared between the two groups. Results At 24 and 72 hours after intervention, the number of patients with hemostasis was significantly higher in the study group than the control group ( χ 2 = 4.935 and 4.948, P= 0.026 and 0.026). Within 30 days after hemostasis, there was no significant difference in the number of rebleeding cases between the two groups (χ 2 = 2.091, P= 0.148). At 7 and 14 days after treatment, the levels of pepsinogenⅠ (PGⅠ), gastrin-17 (G-17), lipid peroxide (LPO), and malondialdehyde (MDA) of patients in the study group were lower than the control group (PGⅠ: t = 3.919 and 3.699, both P<0.001; G-17: t = 3.672 and 4.585, both P<0.001; LPO: t = 7.088 and 6.421, both P<0.001; MDA: t = 4.745 and 5.394, both P<0.001), while the levels of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), nitric oxide (NO), and superoxide dismutase (SOD) of patients in the study group were higher than the control group (bFGF: t = 4.026 and 4.791, both P<0.001; VEGF: t = 4.215 and 4.661, both P<0.001; NO: t = 6.901 and 9.276, both P<0.001; SOD: t = 3.732 and 3.386, P<0.001, P= 0.001). At the end of treatment, the clinical efficacy in the study group was significantly better than the control group (Z= -2.619, P= 0.009). During the treatment period, there was no significant difference in the incidence of adverse reactions between the two groups (χ 2 = 0.898, P= 0.343). Conclusion Ilaprazole combined with digestive endoscopy in the treatment of peptic ulcer bleeding can significantly accelerate hemostasis, effectively reduce the levels of gastric acid secretion and oxidative stress damage, and increase the level of growth factor, thereby promoting ulcer healing, with significant therapeutic effects. |
|
|
|
|
